Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EPS (Basic) (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed EPS (Basic) for 17 consecutive years, with -$0.02 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 108.0% to -$0.02 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.73 through Dec 2025, down 7377.78% year-over-year, with the annual reading at -$6.74 for FY2025, 7388.89% down from the prior year.
  • EPS (Basic) hit -$0.02 in Q4 2025 for Integra Lifesciences Holdings, up from -$0.07 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.64 in Q4 2022 to a low of -$6.31 in Q2 2025.
  • Historically, EPS (Basic) has averaged -$0.09 across 5 years, with a median of $0.26 in 2023.
  • Biggest five-year swings in EPS (Basic): soared 9511.78% in 2021 and later plummeted 3843.75% in 2025.
  • Year by year, EPS (Basic) stood at $0.54 in 2021, then increased by 18.52% to $0.64 in 2022, then tumbled by 59.38% to $0.26 in 2023, then fell by 3.85% to $0.25 in 2024, then crashed by 108.0% to -$0.02 in 2025.
  • Business Quant data shows EPS (Basic) for IART at -$0.02 in Q4 2025, -$0.07 in Q3 2025, and -$6.31 in Q2 2025.